

Haematologica  
HAEMATOL/2017/173419  
Version 3

Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF- $\kappa$ B inhibitor

Tiziana Vaisitti, Federica Gaudino, Samedy Ouk, Maria Moscvin,  
Nicoletta Vitale, Sara Serra, Francesca Arruga, Johannes L.  
Zakrzewski, Hsiou-Chi Liou, John N. Allan, Richard R. Furman, and  
Silvia Deaglio

Disclosures: Hsiou-Chi Liou and Samedy Ouk are co-founder and CEO of ImmuneTarget, Inc., respectively, while Johannes L. Zakrzewski is a consultant/advisory board member. The other authors declare no conflict of interest. This work is supported by the Associazione Italiana per la Ricerca sul Cancro AIRC (IG-17314 to Silvia Deaglio), by the Italian Ministry of Health (Bando Giovani Ricercatori GR-2011-02349282 to Tiziana Vaisitti and GR-2011-02346826 to Silvia Deaglio), by the Leukemia and Lymphoma Society (6465-15 to Johannes L. Zakrzewski) and by ImmuneTarget Inc. IT-901 was provided by ImmuneTarget Inc.

Contributions: TV and SD: designed the study, performed experiments (TV), analyzed and interpreted data, and wrote the paper; FG, MM, NV, SS and FA performed experiments; JNA and RRF: provided patient samples and contributed to data interpretation; SO, HCL, JLZ: provided IT-901, discussed results and contributed to data interpretation.